|
ChemicalBook Optimization Suppliers |
|
| 融点 | >139°C (dec.) | | 沸点 | 814.6±65.0 °C(Predicted) | | 比重(密度) | 1.22±0.1 g/cm3(Predicted) | | 貯蔵温度 | -20°C Freezer, Under inert atmosphere | | 溶解性 | Chloroform (Slightly), DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) | | 外見 | Solid | | 酸解離定数(Pka) | 12.94±0.70(Predicted) | | 色 | White to Off-White |
| | 8-フルオロエリスロマイシン Usage And Synthesis |
| 効能 | 抗生物質, タンパク質合成阻害薬 | | 使用 | A fluorinated derivative of Erythromycin (E649950). A macrolide antibiotic. | | 定義 | ChEBI: An erythromycin derivative that is erythromycin A in which the hydrogen attached to the carbon at position 8 (alpha to the ketone carbonyl group) has been replaced by a fluorine. It has been used (generally as the corresponding monoethyl s
ccinate ester) as an antibacterial drug. | | 応用例（製薬） | A semisynthetic derivative of erythromycin A, supplied for oral administration. It is stable at acid pH due to the presence of the fluorine atom at C-8 of the erythronolide A ring.
It is active against most streptococci (including Str. pneumoniae and Str. agalactiae; MIC50 0.03 mg/L), Mor. catarrhalis, N. gonorrhoeae (MIC50 0.04 mg/L), C. trachomatis (MIC 0.06– 0.125 mg/L), M. genitalium (MIC50 0.007 mg/L) and U. urealyticum (MIC50 0.03 mg/L). It has little or no activity against H. influenzae and M. hominis. Activity against anaerobes is similar to that of erythromycin A. It displays cross-resistance with erythromycin A.
A single 500 mg oral dose achieved a mean peak plasma concentration of 1.2–2 mg/L after 1–2 h. The apparent elimination half-life was 8 h and the volume of distribution 5.5 L/ kg. With repeated doses (500 mg orally every 8 h for 10 doses), plasma concentrations were 0.72 mg/L immediately before and 0.67 mg/L at 4 h after the last dose. Absorption is not significantly affected by food. After administration of a single 375 mg tablet of flurithromycin ethylsuccinate, the mean serum levels at 0.5 h were 0.43 ± 0.35 mg/L. The mean peak serum concentration (1.41 ± 0.49 mg/L) was achieved at 1 h. At 8 and 12 h, the serum levels were 0.14 (± 0.05) and 0.04 (± 0.04) mg/L, respectively. The apparent elimination half-life is 3.94 (± 1.42) h. The apparent half-life in artificial gastric juice was about 40 min.
It is generally well tolerated and has been used successfully for the treatment of lower respiratory tract infections. Availability is limited. |
|